The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Implications of the Human Genome Project for Medical Science
Collins, F. S. (2001) · JAMA · doi:10.1001/jama.285.5.540 · Cited by 838
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
de Leon, J., Susce, M. T., Pan, R.-M., Fairchild, M., Koch, W. H., & Wedlund, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0103 · Cited by 319
Self-citationWhy clinicians are natural bayesians
Gill, C. J., Sabin, L., & Schmid, C. H. (2005) · BMJ · doi:10.1136/bmj.330.7499.1080 · Cited by 268
Pharmacogenetics and drug development: the path to safer and more effective drugs
Roses, A. D. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1432 · Cited by 268
Clinical Pharmacokinetics of Atomoxetine
Sauer, J.-M., Ring, B. J., & Witcher, J. W. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00002 · Cited by 247
DNA SEQUENCING: Massively Parallel Genomics
Fodor, S. P. A. (1997) · Science · doi:10.1126/science.277.5324.393 · Cited by 245
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs
Rogers, J. F., Nafziger, A. N., & Bertino, J. S. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01363-3 · Cited by 215
Pharmacokinetics and drug interactions: update for new antipsychotics.
Ereshefsky, L. (1996) · PubMed · Cited by 211
Brockmöller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Müller‐Oerlinghausen, B., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127494 · Cited by 204
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
Skinner, M. H., Kuan, H., Pan, A., Sathirakul, K., Knadler, M. P., Gonzales, C. R., Yeo, K. P., Reddy, S., Lim, M., Ayan‐Oshodi, M., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.28 · Cited by 195
The challenge of integrating genetic medicine into primary care
Emery, J., & Hayflick, S. (2001) · BMJ · doi:10.1136/bmj.322.7293.1027 · Cited by 192
Pharmacogenetics and pharmacogenomics
Pirmohamed, M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01498.x · Cited by 189
The AmpliChip™ CYP450 Genotyping Test: Integrating a New Clinical Tool
de Leon, J., Susce, M. T., & Murray-Carmichael, E. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256453 · Cited by 187
Self-citationSteimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., & Leucht, S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041327 · Cited by 181
The CYP2C19 Enzyme Polymorphism
Wedlund, P. J. (2000) · Pharmacology · doi:10.1159/000028398 · Cited by 175
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Venlafaxine Serum Levels and CYP2D6 Genotype
Veefkind, A. H., Haffmans, P. M. J., & Hoencamp, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00011 · Cited by 136
The Dosing of Atypical Antipsychotics
de León, J., Armstrong, S. C., & Cozza, K. L. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.3.262 · Cited by 124
Self-citationComparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships
Chou, W.-H., Yan, F., Robbins‐Weilert, D., et al. (2003) · Clinical Chemistry · doi:10.1373/49.4.542 · Cited by 121
Witcher, J. W., Long, A. J., Smith, B. P., Sauer, J., Heilgenstein, J., Wilens, T. E., Spencer, T. J., & Biederman, J. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603321666199 · Cited by 116
de León, J., Susce, M. T., Pan, R.-M., et al. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000177546.34799.af · Cited by 107
Løvlie, R., Daly, A. K., Matre, G. E., Molven, A., & Steen, V. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00006 · Cited by 101
Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00011 · Cited by 94
Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants
Brøsen, K. (2004) · Therapies · doi:10.2515/therapie:2004003 · Cited by 92
Integrating pharmacogenetics into society: in search of a model
Webster, A., Martin, P. A., Lewis, G., & Smart, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1430 · Cited by 89
Laine, K., Tybring, G., Härtter, S., et al. (2001) · PubMed · Cited by 89
PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19
Yu, B., Chen, G., He, N., Ouyang, D., Chen, X., Liu, Z., & Zhou, H. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1255 · Cited by 88
Kubo, M., Koue, T., Inaba, A., Takeda, H., Maune, H., Fukuda, T., & Azuma, J. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.55 · Cited by 84
CYP2D6 polymorphism in a Mexican American population
Mendoza, R., Wan, Y. Y., Poland, R. E., Smith, M. W., Zheng, Y., Berman, N., & Lin, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)00793-7 · Cited by 77
Pilot Study of the Cytochrome P450-2D6 Genotype in a Psychiatric State Hospital
de León, J., Barnhill, J. W., Rogers, T. J., Boyle, J., Chou, W. H., & Wedlund, P. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1278 · Cited by 69
Optimal Dosing With Risperidone
Williams, R. P. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0411 · Cited by 66
CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans
Gonzalez, H. M., Romero‐Tejeda, E. M., Peregrina, A. L. A., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003258170 · Cited by 56
Roberts, R. L., Mulder, R., Joyce, P. R., et al. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.539 · Cited by 50
Quo vadis personalized medicine?
Ruaño, G. (2004) · Personalized Medicine · doi:10.1517/17410541.1.1.1 · Cited by 38
Leucht, S., Hackl, H., Steimer, W., et al. (2000) · Psychopharmacology · doi:10.1007/s002130050006 · Cited by 35
Managing rapid metabolizers of antidepressants
Kraus, R. P., Diaz, P., & McEachran, A. (1996) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1996)4:6<320::aid-da8>3.0.co;2-f · Cited by 14
Holford, T. R., Windemuth, A., & Ruaño, G. (2005) · Personalized Medicine · doi:10.2217/17410541.2.3.239 · Cited by 6
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Some ethnic groups have higher rates of rapid metabolizer status at the hepatic cytochrome P450 enzyme system – potentially translating to higher doses of medication being needed (Cai et al., 2006; De Leon et al., 2006).”
BackgroundTricyclic antidepressant pharmacology and therapeutic drug interactions updated
Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707253 · Cited by 694
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Self-citationPolymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy
Preissner, S. C., Hoffmann, M. F., Preissner, R., Dunkel, M., Gewiess, A., & Preissner, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082562 · Cited by 278
Metadata
- Authors
- de Leon, J., Armstrong, S. C., & Cozza, K. L.
- Venue
- Psychosomatics
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 47
- Issue
- 1
- Pages
- 75-85
- ISSN
- 0033-3182 (ISSN-L)
- OpenAlex
- W2163246271
- Cited by
- 300
- References
- 42
- FWCI
- 21.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.